Interferon-γ-dependent infiltration of human T cells into neuroblastoma tumors in vivo

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6602-6608

  Reid, Gregor S D ^a   Shan, Xiaochuan ^b   Coughlin, Christina M ^a   Lassoued, Wiem ^b   Pawel, Bruce R ^a   Wexler, Leonard H ^f   Thiele, Carol J ^d   Tsokos, Maria ^d   Pinkus, Jack L ^e   Pinkus, Geraldine S ^e   Grupp, Stephan A ^a,c   Vonderheide, Robert H ^b,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA1B INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOPSY; CELL KILLING; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ENGRAFTMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; CELL LINE, TUMOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; PILOT PROJECTS; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 70350719347     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0829     Document Type: Article

References (28)

1. Garcia-Lora A, Algarra I, Collado A, Garrido F. Tumour immunology, vaccination and escape strategies. Eur J Immunogenet 2003;30:177-183 (Pubitemid 36724001)
2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-384
3. Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64. (Pubitemid 35398865)
4. Meissner M, Reichert TE, Kunkel M, et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005;11:2552-2560 (Pubitemid 40569453)
5. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigenprocessing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999;154:745-754 (Pubitemid 29122593)
6. Tao J, Li Y, Liu Y, et al. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors. Br J Dermatol 2008;158:88-94. (Pubitemid 350221920)
7. Ogino T, Shigyo H, Ishii H, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006;66:9281-9289 (Pubitemid 44521150)
8. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 2008;57:197-206. (Pubitemid 350159921)
9. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008;57:1719-1726
10. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-272 (Pubitemid 23117076)
11. Seliger B, Hohne A, Knuth A, et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 1996;56:1756-1760 (Pubitemid 26118209)
12. Johnsen A, France J, Sy MS, Harding CV. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res 1998;58:3660-3667 (Pubitemid 28376566)
13. Weidanz JA, Nguyen T, Woodburn T, et al. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol 2006;177:5088-5097 (Pubitemid 44527579)
14. Merritt RE, Yamada RE, Crystal RG, Korst RJ. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy. J Thorac Cardiovasc Surg 2004;127:355-364
15. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-γ production within the tumor microenvironment influences antitumor immunity. J Immunol 2008;180:3132-3139
16. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216 (Pubitemid 37328872)
17. Coughlin CM, Fleming MD, Carroll RG, et al. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006;24:5725-5734
18. Main EK, Lampson LA, Hart MK, Kornbluth J, Wilson DB. Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol 1985;135:242-246
19. Wolfl M, Jungbluth AA, Garrido F, et al. Expression of MHC class I, MHC class II, cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 2005;54:400-406 (Pubitemid 40238934)
20. Raffaghello L, Prigione I, Bocca P, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005;24:4634-4644 (Pubitemid 41032601)
21. Levine BL, Bernstein WB, Connors M, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997;159:5921-5930 (Pubitemid 127471527)
22. Yang X, Merchant MS, Romero ME, et al. Induction of caspase 8 by interferon γ renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2al so contributes to TRAIL resistance in NB. Cancer Res 2003;63:1122-1129 (Pubitemid 36278447)
23. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004;103:2046-2054
24. Raffaghello L, Prigione I, Airoldi I, et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett 2005;228:155-161 (Pubitemid 41188437)
25. Lampson LA, George DL. Interferon-mediated induction of class I MHC products in human neuronal cell lines: analysis of HLA and â2-m RNA, HLA-A and HLA-B proteins and polymorphic specificities. J Interferon Res 1986;6:257-265
26. Zhang QJ, Li XL, Wang D, et al. Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell crosspriming and promotes adaptive T cell responses. PLoS ONE 2008;3:e3097.
27. Kunz M, Toksoy A, Goebeler M, Engelhardt E, Brocker E, Gillitzer R. Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J Pathol 1999;189:552-558
28. Tay SS, McCormack A, Lawson C, Rose ML. IFN-γ reverses the stop signal allowing migration of antigen-specific T cells into inflammatory sites. J Immunol 2003;170:3315-3322 (Pubitemid 36302210)